Testing for drug resistance in tuberculosis more quickly and accurately
Development of a Rapid Phenotypic Pyrazinamide Susceptibility Testing for Mycobacterium tuberculosis Using Well-Standardized Protocol
This study is working on a quick and dependable test to see if tuberculosis bacteria can resist a key medicine called pyrazinamide, which will help doctors choose the best treatment for patients and improve their health, especially in places where tuberculosis is common.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Pza Innovation LLC NIH-funded |
| Lab location | 1 site (Towson, United States) |
| Project ID | NIH-11005406 on NIH RePORTER |
What this research studies
This research focuses on developing a rapid and reliable test for determining the susceptibility of Mycobacterium tuberculosis to pyrazinamide, a key drug in tuberculosis treatment. By creating a standardized protocol for this testing, the research aims to improve the accuracy of identifying drug-resistant tuberculosis cases. This will help healthcare providers make better treatment decisions, ultimately leading to improved patient outcomes. The methodology involves streamlining the testing process to ensure it is both efficient and cost-effective, making it accessible even in high-burden areas.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those suspected of having drug-resistant strains.
Not a fit: Patients who do not have tuberculosis or those with other unrelated health conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more accurate treatment for tuberculosis patients, reducing the risk of complications and improving recovery times.
How similar studies have performed: Previous research has shown that improving drug susceptibility testing can significantly enhance treatment outcomes for tuberculosis patients, indicating a promising avenue for this approach.
Where this research is happening
Towson, United States
- Pza Innovation LLC — Towson, United States (Active)
Researchers
- Principal investigator: Shi, Wanliang — Pza Innovation LLC
- Study coordinator: Shi, Wanliang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.